以岭药业(002603.SZ)：盐酸伐昔洛韦片获得药品注册证书

Core Viewpoint - Yiling Pharmaceutical's subsidiary, Yiling Wanzhou International Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the marketing authorization application of Valaciclovir Hydrochloride Tablets, indicating a significant advancement in the company's product portfolio and potential market opportunities [1] Group 1: Product Approval - Yiling Wanzhou has obtained the drug registration certificate for Valaciclovir Hydrochloride Tablets from the National Medical Products Administration [1] - Valaciclovir is a prodrug of Acyclovir, which rapidly converts to Acyclovir in the body, competitively inhibiting viral DNA polymerase to block viral DNA synthesis [1] Group 2: Indications and Market Potential - The primary indications for Valaciclovir Hydrochloride Tablets include the treatment of shingles, treatment of herpes simplex virus infections, and prevention (suppression) of recurrent herpes simplex virus infections [1] - Valaciclovir Hydrochloride Tablets are classified as a Category B drug in the National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug Catalog (2025 Edition) [1]